11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Cyclooxygenase-2 in cancer: A review : HASHEMI et al.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cyclooxygenase-2 (COX-2) is frequently expressed in many types of cancers exerting a pleiotropic and multifaceted role in genesis or promotion of carcinogenesis and cancer cell resistance to chemo- and radiotherapy. COX-2 is released by cancer-associated fibroblasts (CAFs), macrophage type 2 (M2) cells, and cancer cells to the tumor microenvironment (TME). COX-2 induces cancer stem cell (CSC)-like activity, and promotes apoptotic resistance, proliferation, angiogenesis, inflammation, invasion, and metastasis of cancer cells. COX-2 mediated hypoxia within the TME along with its positive interactions with YAP1 and antiapoptotic mediators are all in favor of cancer cell resistance to chemotherapeutic drugs. COX-2 exerts most of the functions through its metabolite prostaglandin E2. In some and limited situations, COX-2 may act as an antitumor enzyme. Multiple signals are contributed to the functions of COX-2 on cancer cells or its regulation. Members of mitogen-activated protein kinase (MAPK) family, epidermal growth factor receptor (EGFR), and nuclear factor-κβ are main upstream modulators for COX-2 in cancer cells. COX-2 also has interactions with a number of hormones within the body. Inhibition of COX-2 provides a high possibility to exert therapeutic outcomes in cancer. Administration of COX-2 inhibitors in a preoperative setting could reduce the risk of metastasis in cancer patients. COX-2 inhibition also sensitizes cancer cells to treatments like radio- and chemotherapy. Chemotherapeutic agents adversely induce COX-2 activity. Therefore, choosing an appropriate chemotherapy drugs along with adjustment of the type and does for COX-2 inhibitors based on the type of cancer would be an effective adjuvant strategy for targeting cancer.

          Related collections

          Author and article information

          Journal
          Journal of Cellular Physiology
          J Cell Physiol
          Wiley
          00219541
          May 2019
          May 2019
          October 20 2018
          : 234
          : 5
          : 5683-5699
          Affiliations
          [1 ]Department of Medical Biotechnology; School of Advanced Technologies in Medicine, Tehran University of Medical Sciences; Tehran Iran
          [2 ]Radiology and Nuclear Medicine Department; School of Paramedical Sciences, Kermanshah University of Medical Sciences; Kermanshah Iran
          [3 ]Department of Anatomy; School of Medicine, Tehran University of Medical Sciences; Tehran Iran
          [4 ]Departments of Medical Physics and Radiology; Faculty of Paramedical Sciences, Kashan University of Medical Sciences; Kashan Iran
          [5 ]Department of Anatomy; School of Medicine, Kurdistan University of Medical Sciences; Sanandaj Iran
          Article
          10.1002/jcp.27411
          30341914
          d3e1c7ee-a93d-4bf6-99fc-0029cacdc946
          © 2018

          http://doi.wiley.com/10.1002/tdm_license_1.1

          http://onlinelibrary.wiley.com/termsAndConditions#vor

          History

          Comments

          Comment on this article